Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Phio PharmaceuticalsPHIO 30 12-1 Month Momentum % is -57.81% as of Aug. 05, 2026. GuruFocus rates PHIO with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 1,361 Biotechnology companies, Phio Pharmaceuticals ranks worse than 84.35% on this metric.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-08-05), Phio Pharmaceuticals's 12-1 Month Momentum % is -57.81%.
The industry rank for Phio Pharmaceuticals's 12-1 Month Momentum % or its related term are showing as below:
PHIO's 12-1 Month Momentum % is ranked worse than 84.35% of 1361
companies
in the Biotechnology industry
Industry Median: -14.9
vs PHIO: -57.81
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Phio Pharmaceuticals 12-1 Month Momentum % Related Terms
PHIO vs CALC, INTS, ANEB: 12-1 Month Momentum % Comparison
For the Biotechnology subindustry, Phio Pharmaceuticals's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Phio Pharmaceuticals 12-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Phio Pharmaceuticals's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Phio Pharmaceuticals's 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a 12-1 Month Momentum % of -57.81% mean?
Phio Pharmaceuticals (PHIO) has a 12-1 Month Momentum % of -57.81% as of Aug. 05, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Phio Pharmaceuticals and its competitors. According to the industry distribution chart, Phio Pharmaceuticals ranks #1148 out of 1361 companies in the Biotechnology industry, placing it in the top 84.3%.
Is Phio Pharmaceuticals' 12-1 Month Momentum % too high?
Phio Pharmaceuticals' current 12-1 Month Momentum % is -57.81%. Based on the distribution chart, Phio Pharmaceuticals ranks #1148 out of 1361 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Phio Pharmaceuticals has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Phio Pharmaceuticals' 12-1 Month Momentum % compare to CALC and INTS?
According to the Biotechnology industry distribution chart, Phio Pharmaceuticals ranks #1148 out of 1361 companies for 12-1 Month Momentum %. This places Phio Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Biotechnology company?
A good 12-1 Month Momentum % depends on the Biotechnology industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Phio Pharmaceuticals and its competitors. Phio Pharmaceuticals's current 12-1 Month Momentum % is -57.81%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Phio Pharmaceuticals stock overvalued right now?
Phio Pharmaceuticals (PHIO) has a current 12-1 Month Momentum % of -57.81%. The current 12-1 Month Momentum % is -57.81%. Phio Pharmaceuticals' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Phio Pharmaceuticals (PHIO), the current 12-1 Month Momentum % is -57.81% as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.
30GF Score
Get the complete analysis for PHIO
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHIO has been successfully added to your 
